ClinicalTrials.gg
CompletedNCT07541677Updated Oct 27, 2026

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity

An observational study in Obesity, sponsored by Singapore General Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Singapore General Hospital · Observational

How we know

Updated Oct 27, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
160
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.

Enrollment
9th of 15
160 · median 200
Started
2025
with 7 others
Observational
15 of 83
3 open now
Registered
69th of 83
by date
Lead sponsor
4 of 83
Singapore General Hospital

Among the 83 studies in Obesity with a site in Singapore, this one is the 9th largest by enrollment of the 15 observational ones that give a count, is one of 8 that started in 2025, is one of 15 observational ones, and was the 69th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Obesity with a site in Singapore, or all of them as a file.
02

Study summary

Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.

In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.

The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.

Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with obesity seeking treatment at Singapore General Hospital Obesity Centre

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 27.5kg/m2
  • able to provide .

Exclusion criteria

Exclusion Criteria:

  • unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
  • pregnant women
  • history of bariatric procedures or surgeries
  • on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
160 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sarcopenia

    Skeletal muscle mass Skeletal muscle mass measurement will be obtained via bioimpedance analysis using the TANITA MC 780 MA Multi-frequency Segmental Body Composition Analyser. Low skeletal muscle mass will be defined by percentage of skeletal muscle mass divided by body weight of ≤ 37% in males and ≤ 27.6% in females.

    Time frame: Outcome measures will be recorded at baseline only.

  2. Handgrip strength

    Handgrip strength will be measured using the Jamar handgrip dynamometer. Two trials will be performed for each hand, and the maximum strength will be used for diagnosis.

    Time frame: Outcome measures will be recorded at baseline only.

  3. 5-time chair stand test

    Time taken (seconds) to perform 5 sit-to-stand repetitions

    Time frame: Outcome measures will be recorded at baseline only.

  4. 30-second sit-to-stand test

    Number of sit-to-stand repetitions performed in 30 seconds

    Time frame: Outcome measures will be recorded at baseline only.

Secondary outcomes

  1. Aerobic capacity

    The study will use a validated non-exercise prediction model comprising a physical activity questionnaire to estimate peak oxygen uptake, VO2 milliliter/kg/minute (ml/kg/min). This simple physical activity questionnaire consists of age, gender, height, weight, estimated maximum heart rate, frequency of exercise, length of time for each workout, intensity of each workout, waistline diameter, and resting heart rate. It will be self-administered or administered with the assistance of the clinical research coordinator if required.

    Time frame: At baseline

  2. Physical activity questionnaire

    Number of minutes per week spent on moderate to vigorous physical activity will be recorded

    Time frame: At baseline

  3. Dietary questionnaire

    72 hour dietary recall questionnaire will be administered and dietary macronutrient composition will be calculated

    Time frame: At baseline

07

Study locations

1 site
  • Singapore General Hospital
    Singapore, Singapore
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2025 to primary completion in May 2026, 12 months.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Jul 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Apr 21, 2026
StartActual
May 26, 2025
Primary completionActual
May 31, 2026
CompletionActual
Jul 31, 2026was Apr 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Study completion
Apr 2027→Jul 31, 2026 (actual)
Oct 27, 2026
Enrollment
300 (estimated)→160 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    Study completion Apr 2027→Jul 31, 2026 (now actual)
    Enrollment 300 (estimated)→160 (actual)
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07541677
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 26, 2025
Primary completion
May 31, 2026
Completion
Jul 31, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion